{"id":"pixantrone-rituximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Cardiotoxicity"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pixantrone intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks and apoptosis in rapidly dividing cells. Rituximab binds CD20 on B-cell lymphomas, triggering antibody-dependent cellular cytotoxicity and direct cell death. Together, they provide dual mechanisms targeting lymphoid malignancies.","oneSentence":"Pixantrone is a topoisomerase II inhibitor that damages cancer cell DNA, combined with rituximab, a CD20-targeting monoclonal antibody that depletes B cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:12.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)"}]},"trialDetails":[{"nctId":"NCT03458260","phase":"PHASE2","title":"Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2018-12-26","conditions":"Aggressive Non-Hodgkin Lymphoma","enrollment":74},{"nctId":"NCT00268853","phase":"PHASE2","title":"A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2005-11","conditions":"Diffuse Large-Cell Lymphoma","enrollment":124},{"nctId":"NCT02678299","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2016-02","conditions":"Malignant Lymphoma","enrollment":60},{"nctId":"NCT01321541","phase":"PHASE3","title":"Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2011-04-20","conditions":"Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma","enrollment":312},{"nctId":"NCT00551239","phase":"PHASE3","title":"Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"CTI BioPharma","startDate":"2007-08","conditions":"Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT00577161","phase":"PHASE3","title":"Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL","status":"WITHDRAWN","sponsor":"CTI BioPharma","startDate":"2007-09","conditions":"Non-Hodgkin's Lymphoma","enrollment":""},{"nctId":"NCT01491841","phase":"PHASE1","title":"IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Anne Beaven, MD","startDate":"2011-11-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":33},{"nctId":"NCT00088530","phase":"PHASE3","title":"BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2004-07","conditions":"Lymphoma, Non-Hodgkin","enrollment":140},{"nctId":"NCT00060671","phase":"PHASE3","title":"Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"CTI BioPharma","startDate":"2005-01","conditions":"Lymphoma, Follicular, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular","enrollment":800},{"nctId":"NCT00060684","phase":"PHASE1","title":"Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2001-12","conditions":"Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular","enrollment":30},{"nctId":"NCT00069966","phase":"PHASE2","title":"Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse","status":"UNKNOWN","sponsor":"Theradex","startDate":"2003-04","conditions":"Lymphoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pixantrone + Rituximab","genericName":"Pixantrone + Rituximab","companyName":"CTI BioPharma","companyId":"cti-biopharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pixantrone is a topoisomerase II inhibitor that damages cancer cell DNA, combined with rituximab, a CD20-targeting monoclonal antibody that depletes B cells. Used for Relapsed or refractory diffuse large B-cell lymphoma (DLBCL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}